Wealth Enhancement Advisory Services’s Castle Biosciences CSTL Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio CSTL Stock Details CSTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$299K	Buy	+8,868	New	+$268K	﹤0.01%	3347

Other funds holding CSTL

Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return

KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return

Harbor Capital Advisors Chicago, Illinois $1.48B AUM 30.88% 1-Year Est. Return

FBT

First Bank & Trust Brookings, South Dakota $687M AUM 18.35% 1-Year Est. Return

Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return

DekaBank Deutsche Girozentrale Frankfurt, Germany $87.8B AUM 20.94% 1-Year Est. Return

Diversify Advisory Services Sandy, Utah $6.69B AUM 18.85% 1-Year Est. Return

Diversify Wealth Management Sandy, Utah $6.69B AUM 22.4% 1-Year Est. Return

Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return

Oak Harvest Investment Services Houston, Texas $1.07B AUM 32.83% 1-Year Est. Return

Wealth Enhancement Advisory Services's CSTL Position: Q3 2026 in Review

Wealth Enhancement Advisory Services opened a new position in Castle Biosciences (CSTL) in Q3 2026: 8,868 shares worth $299K. The stake represents ﹤0.01% of the portfolio and ranks #3347 among its holdings.

33 funds tracked by Wall St. Rank hold CSTL as of Q3 2026.

Wealth Enhancement Advisory Services held 8,868 shares of Castle Biosciences worth $299K as of Q3 2026.
Castle Biosciences was a new Wealth Enhancement Advisory Services position in Q3 2026.
Castle Biosciences made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q3 2026, its #3347 holding.
33 funds tracked by Wall St. Rank held Castle Biosciences as of Q3 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q3 2026, filed 13 Oct 2026.